SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Algernon Pharmaceuticals Inc. (AGNPF) , forward earnings yield 2,000.00%.
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Forward P/E 0.1
Overall SharesGrow Score: 21/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — AGNPF
Valuation Multiples
P/E (TTM)0.0
Forward P/E0.1
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.06
Forward EPS (Est.)$0.69
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield2,000.00%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-9.75 |
$0.00 |
$-6.88M |
- |
| 2017 |
$-1.84 |
$0.00 |
$-1.89M |
- |
| 2018 |
$-0.83 |
$0.00 |
$-938K |
- |
| 2019 |
$-1.06 |
$0.00 |
$-1.9M |
- |
| 2020 |
$-2.42 |
$0.00 |
$-8.54M |
- |
| 2021 |
$-1.24 |
$0.00 |
$-7.73M |
- |
| 2022 |
$-0.87 |
$0.00 |
$-6.05M |
- |
| 2023 |
$-0.45 |
$0.00 |
$-6.78M |
- |
| 2024 |
$-0.03 |
$0.00 |
$-503K |
- |
| 2025 |
$-0.06 |
$0.00 |
$-1.72M |
- |
